5 active not recruiting, 5 completed, 5 recruiting, 3 unknown. 9 Phase 2, 4 Not applicable, 3 Phase 3, 1 Phase 1.
Follow High-Risk Cancer: new trials by email Literature Review of High-Risk Cancer trials Research Report on High-Risk Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 2 | Not yet recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 100 | 2026-09-01 | 2026-08-14 |
| SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 3 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 204 | 2026-05-20 | 2026-07-01 |
| SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 2 | Completed | Sixth Affiliated Hospital, Sun Yat-sen University | 49 | 2025-04-02 | 2026-08-04 |
| Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma Maintenance Therapy with Toripalimab and Capecitabine, Maintenance Therapy with Capecitabine - Nasopharyngeal Carcinoma, High-Risk Cancer | Phase 3 | Recruiting | Jiangxi Provincial Cancer Hospital | 264 | 2024-03-07 | 2026-05-15 |
| Adherence to Lung Cancer Screening by Low-dose Thoracic CT in Haut-Rhin Department, France. Low Dose chest CT Scan for Lung Cancer Screening - High-Risk Cancer, Lung Cancer | Not applicable | Active not recruiting | Groupe Hospitalier de la Region de Mulhouse et Sud Alsace | 126 | 2023-11-06 | 2026-05-08 |
| Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation multi-kinase inhibitors in combination with bevacizumab - Liver Transplant; Complications, Hepatocarcinoma | Phase 2 | Not yet recruiting | Peking Union Medical College Hospital | 88 | 2023-09-01 | 2023-09-18 |
| Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations Olaparib, LHRH agonist - Prostate Cancer, BRCA1 Mutation | Phase 2 | Active not recruiting | Rana McKay, MD | 32 | 2023-02-01 | 2026-07-10 |
| Taiwan Real-world LDCT Screening Behavior and Outcome Research for High Risk Subjects Based on Health Promotion Administration Low dose computed tomography - Lung Cancer, High-Risk Cancer | Recruiting | Gee-Chen Chang | 6618 | 2022-12-15 | 2025-09-10 | |
| Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal Specimens Anal Intraepithelial Neoplasia 2, Anal Intraepithelial Neoplasia 1 | Recruiting | European Institute of Oncology | 200 | 2022-06-17 | 2024-03-26 | |
| Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region Regular care with additionally administration of questionnaires - Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck | Completed | Maastricht University Medical Center | 78 | 2022-02-28 | 2026-01-06 | |
| A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102) Anti-PD-1 monoclonal antibody, Pegaspargase, Gemcitabine - Extranodal NK-T-Cell Lymphoma, Early-stage | Phase 2 | Completed | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 54 | 2021-11-10 | 2026-08-20 |
| Needs and Preferences of Patients With Head-neck Cutaneous SCC Regular care with additional administration of a semi-structured interview - Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck | Active not recruiting | Maastricht University Medical Center | 15 | 2021-11-01 | 2025-04-04 | |
| Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer Tremelimumab - Bladder Cancer, High-Risk Cancer | Phase 1 / Phase 2 | Withdrawn | University of British Columbia | 2021-09-01 | 2023-10-31 | |
| Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study Blinatumomab - Philadelphia-Negative ALL, High-Risk Cancer | Phase 2 | Unknown | Israeli Medical Association | 110 | 2021-01-01 | 2021-05-07 |
| Three Fraction Radiation to Induce Immuno-Oncologic Response Neoadjuvant radiotherapy - High-Risk Cancer, Locally Advanced Breast Cancer | Not applicable | Active not recruiting | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 40 | 2020-09-02 | 2026-02-20 |
| Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis Hematopoietic stem cell transplant, Ruxolitinib, Hydroxyurea - Myelofibrosis, High-Risk Cancer | Active not recruiting | University Health Network, Toronto | 90 | 2020-08-05 | 2026-07-06 | |
| A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations Empegfilgrastim - Solid Tumor, High-Risk Cancer | Unknown | Moscow Clinical Scientific Center | 285 | 2020-04-28 | 2021-06-02 | |
| Prevent Cancer- Greenville Cancer, High-Risk Cancer | Recruiting | Prisma Health-Upstate | 1000 | 2018-11-08 | 2026-02-17 | |
| Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder Cancer Adjuvant Radiotherapy - High-Risk Cancer, Urothelial Carcinoma Bladder | Not applicable | Unknown | Cairo University | 100 | 2018-08-01 | 2021-02-09 |
| Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients Bortezomib following nonmyeloablative allogeneic transplant - Multiple Myeloma, High-Risk Cancer | Phase 2 | Completed | Maisonneuve-Rosemont Hospital | 40 | 2014-11-01 | 2023-10-19 |
Showing 20 of 23. Sign in to see all of them.
Rectal Neoplasms (3) · Carcinoma, Squamous Cell (2) · Lung Neoplasms (2) · Neoplasms (2) · Patient Satisfaction (2) · Skin Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Anus Neoplasms (1) · Bone Marrow Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Gastrointestinal Neoplasms (1) · Infections (1) · Lymphoma, Extranodal NK-T-Cell (1) · Multiple Myeloma (1)
Neoplasms (16) · Neoplasms by Site (14) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Neoplasms by Histologic Type (6) · Gastrointestinal Diseases (5) · Carcinoma (4) · Colorectal Neoplasms (4) · Gastrointestinal Neoplasms (4) · Intestinal Diseases (4) · Intestinal Neoplasms (4) · Neoplasms, Glandular and Epithelial (4) · Rectal Diseases (4) · Behavior (3) · Head and Neck Neoplasms (3)
spartalizumab (4) · Bevacizumab (3) · Surgical Procedures, Operative (3) · Cetuximab (2) · Ascorbic Acid (1) · Bortezomib (1) · Capecitabine (1) · Diet, Ketogenic (1) · Fenretinide (1) · Gemcitabine (1) · Gonadotropin-Releasing Hormone (1) · Goserelin (1) · Hydroxyurea (1) · Leuprolide (1) · Maintenance (1)
Sixth Affiliated Hospital, Sun Yat-sen University (3) · European Institute of Oncology (2) · Maastricht University Medical Center (2) · Cairo University (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Gee-Chen Chang (1) · Groupe Hospitalier de la Region de Mulhouse et Sud Alsace (1) · Israeli Medical Association (1) · Jiangxi Provincial Cancer Hospital (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Maisonneuve-Rosemont Hospital (1) · Moscow Clinical Scientific Center (1) · Peking Union Medical College Hospital (1) · Prisma Health-Upstate (1) · RWTH Aachen University (1)
China (6) · Canada (4) · Italy (2) · Netherlands (2) · United States (2) · Egypt (1) · France (1) · Germany (1) · Israel (1) · Russia (1) · Taiwan (1)
K Mosterd, MD, PhD (2) · Alexey Tryakin, MD, PhD, professor (1) · Brian Yaremko, MD (1) · Guohui Wan, PhD. (1) · Inna Ganshina, MD, PhD (1) · Jennifer Gonzalez (1) · Jingao Li (1) · Joe Stephenson, MD (1) · Juan Huang, PhD. (1) · Jun Huang, PhD (1) · Jun Huang, PhD. (1) · Lyudmila Zhukova, MD, PhD, professor (1) · Michael Lock, MD (1) · Mikhail Fedyanin, MD, PhD, professor (1) · Mohamed Zaghloul, MD (1)
PMID 1612951, PMID 29188298, PMID 36710203, PMID 41671463, PMID 41826137
2009 (1)